NGS Panels
Targeted next-generation sequencing of clinically relevant genes used as a first-line genetic evaluation for autism, developmental delay and related conditions.
Overview
- Detects variants in dozens to hundreds of neurodevelopmental genes.
- Non-invasive sample: saliva or cheek swab.
- Clinical report with actionable interpretation for physicians.
About NGS Panels — targeted genetic testing for neurodevelopment
NGS Panels use targeted next-generation sequencing to examine a curated set of genes associated with neurodevelopmental disorders, autism spectrum disorder (ASD), intellectual disability and developmental delay. Panels are designed to balance breadth and clinical relevance: they focus on genes with well-established links to the condition, producing high-quality, actionable results at lower cost and faster turnaround than whole-exome or whole-genome sequencing.
Key benefits
- Focused diagnosis: detects pathogenic and likely-pathogenic variants in clinically actionable genes.
- Non-invasive collection: saliva or cheek swab—easy for children and adults.
- Actionable report: clinical interpretation and recommendations to help guide next steps.
Who should consider NGS Panels?
- Individuals (children or adults) with developmental delay, language delay, or autism-like features.
- Families seeking a cost-effective first-line genetic test before broader sequencing.
- Clinicians wanting faster, targeted results to guide immediate clinical decisions.
Sample collection guidance
Do not eat, drink, smoke, chew gum or brush teeth 30 minutes prior to collection. Follow kit instructions exactly; contamination reduces DNA quality and may invalidate the result. Ship specimens promptly using the provided packaging.